Axillary Hyperhidrosis - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Axillary Hyperhidrosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Axillary Hyperhidrosis - Pipeline Review, H1 2016', provides an overview of the Axillary Hyperhidrosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis
- The report reviews pipeline therapeutics for Axillary Hyperhidrosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Axillary Hyperhidrosis therapeutics and enlists all their major and minor projects
- The report assesses Axillary Hyperhidrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Axillary Hyperhidrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Axillary Hyperhidrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Axillary Hyperhidrosis Overview 6
Therapeutics Development 7
Pipeline Products for Axillary Hyperhidrosis - Overview 7
Axillary Hyperhidrosis - Therapeutics under Development by Companies 8
Axillary Hyperhidrosis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Axillary Hyperhidrosis - Products under Development by Companies 11
Axillary Hyperhidrosis - Companies Involved in Therapeutics Development 12
Allergan Plc 12
Brickell Biotech, Inc. 13
Dermira Inc. 14
GlaxoSmithKline Plc 15
Revance Therapeutics, Inc. 16
TheraVida, Inc. 17
Axillary Hyperhidrosis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
(oxybutynin chloride + pilocarpine hydrochloride) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ANT-1207 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ANT-1403 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
daxibotulinumtoxin A - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
DRM-04 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
oxybutynin chloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
sofpironium bromide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
umeclidinium bromide - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Axillary Hyperhidrosis - Recent Pipeline Updates 38
Axillary Hyperhidrosis - Product Development Milestones 45
Featured News & Press Releases 45
Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating 45
Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis 46
Jan 07, 2016: Dermira Provides DRM04 Development Program Update 47
Dec 23, 2015: Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis 48
Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis 49
Sep 28, 2015: Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines 49
Sep 09, 2015: Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis 50
Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis 51
Jun 03, 2015: Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate 52
Feb 05, 2015: Dermira Announces Positive Phase 2b Results for DRM04 in Patients with Hyperhidrosis 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for Axillary Hyperhidrosis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Axillary Hyperhidrosis - Pipeline by Allergan Plc, H1 2016 12
Axillary Hyperhidrosis - Pipeline by Brickell Biotech, Inc., H1 2016 13
Axillary Hyperhidrosis - Pipeline by Dermira Inc., H1 2016 14
Axillary Hyperhidrosis - Pipeline by GlaxoSmithKline Plc, H1 2016 15
Axillary Hyperhidrosis - Pipeline by Revance Therapeutics, Inc., H1 2016 16
Axillary Hyperhidrosis - Pipeline by TheraVida, Inc., H1 2016 17
Assessment by Monotherapy Products, H1 2016 18
Assessment by Combination Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Axillary Hyperhidrosis Therapeutics - Recent Pipeline Updates, H1 2016 38